Background: Pulmonary hypertension is a severe pulmonary vascular disease leading to rapid deterioration and death. Histological and clinical evidence suggests that smooth muscle proliferation is part of the pathogenesis of the disease. Human herpesvirus 8 (HHV-8) is a γ-herpesvirus that is implicated in malignancies and in Kaposi’s sarcoma. Recently, the association of HHV-8 with idiopathic pulmonary arterial hypertension (PAH) has been found. Objective: The aim of this study was to investigate the presence of HHV-8 in the lung tissue of Israeli patients with PAH. Method: The presence of HHV-8 sequences was investigated by polymerase chain reaction examination in 6 biopsies of patients with pulmonary hypertension. Three patients had idiopathic pulmonary hypertension, 2 patients pulmonary venoocclusive disease, and 1 patient pulmonary hypertension associated with mixed connective tissue disease. Result: We did not find any association between HHV-8 and PAH in these Israeli patients, as all the samples were negative for polymerase chain reaction. Conclusion: Our findings, together with the epidemiological data of HHV-8 prevalence and incidence rates of Kaposi’s sarcoma and PAH in Israel, provide further evidence which argues against an association between HHV-8 infection and PAH.

Keywords:
Human herpesvirus 8, Pulmonary arterial hypertension
1.
Chang Y, Cesarman E, Pessin MS, et al: Identification of herpesvirus like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266:1865–1869.
2.
Cohen A, Wolf DG, Guttman-Yassky E, Sarid D: Kaposi sarcoma associated with herpesvirus: clinical, diagnostic and epidemiologic aspects. Crit Rev Clin Lab Sci 2005;42:101–153.
3.
Belec L, Mohamed AS, Authier FJ, et al: Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman’s disease. Blood 1999;93:3643–3653.
4.
Rubin LJ: Primary pulmonary hypertension. N Engl J Med 1997;336:111–117.
5.
Galie N, Manes A, Uguccioni L, et al: Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest 1998;114:184s–194s.
6.
Cool CD, Rai PR, Yeager ME, et al: Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003;349:1113–1122.
7.
Bull T, Cool CD, Serls AE, et al: Primary pulmonary hypertension, Castleman’s disease and human herpesvirus-8. Eur Respir J 2003;22:403–407.
8.
Montani D, Achouh L, Marsellin AG, et al: Reversibility of pulmonary arterial hypertension in HIV/HHV8 associated Castelman’s disease. Eur Respir J 2005;26:969–972.
9.
Katano H, Ito K, Shibuya K, et al: Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. J Infect Dis 2005;191:743–745.
10.
Henke-Gendo C, Mengel M, Hoeper M, et al: Absence of Kaposi’s sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2005;172:1581–1585.
11.
Henke-Gendo C, Schulz TF, Hoeper MM: HHV-8 in pulmonary hypertension. N Engl J Med 2004;350:194–195.
12.
Laney AS, De Marco T, Peters JS, et al: Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest 2005;127:762–767.
13.
Montani D, Marsellin AG, Sitbon O, et al: Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 2005;19:1239–1240.
14.
Nicastri E: Human herpesvirus 8 and pulmonary hypertension. Emerg Infect Dis 2005;11:1480–1482.
15.
Appelbaum L, Yigla M, Bendayan D, et al: Primary pulmonary hypertension in Israel: a national survey. Chest 2001;119:1801–1806.
16.
Davidovici B, Karakis I, Bourboulia D, et al: Seroepidemiology and molecular epidemiology of Kaposi’s sarcoma-associated herpesvirus among Jewish population groups in Israel. J Natl Cancer Inst 2001;93:194–202.
17.
Guttman-Yassky E, Bar-Chana M, Yukelson A, et al: Epidemiology of classic Kaposi’s sarcoma in the Israeli Jewish population between 1960 and 1998. Br J Cancer 2003;89:1657–1660.
18.
Iscovich J, Boffetta P, Franceschi S, et al: Classic Kaposi sarcoma: epidemiology and risk factors. Cancer 2000;88:500–517.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.